Cyclacel Pharmaceuticals Announces Multiple Clinical Abstracts Selected for Presentation at the ASH 2019 Annual Meeting
06 nov. 2019 09h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Announces First Patient Treated in a Phase 1/2 Study of Sapacitabine and Venetoclax in Relapsed or Refractory AML or MDS Patients
22 juil. 2019 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., July 22, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Announces Presentation of Phase 1 Data of Sapacitabine Regimen in Patients With BRCA Mutant Breast Cancer at AACR 2019
01 avr. 2019 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., April 01, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Sapacitabine With Olaparib in BRCA Mutant Breast Cancer
10 sept. 2018 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Announces Notice of Grant of New European Patent Covering Sapacitabine Pharmaceutical Formulations
21 févr. 2018 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral...
Cyclacel Announces Presentation of Results From Phase 3 Seamless Study at Ash Annual Meeting
12 déc. 2017 07h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) "Cyclacel" or the "Company"), a biopharmaceutical company developing oral...
Cyclacel Pharmaceuticals Announces That Full Results From the Phase 3 Seamless Trial Have Been Selected for Oral Presentation at ASH 2017 Annual Meeting
01 nov. 2017 09h02 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell...
Cyclacel Reports Updated Data From Its DNA Damage Response Program on Seliciclib and Sapacitabine Combination in Patients With Solid Tumors at ASCO
06 juin 2016 10h00 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., June 06, 2016 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), reported today updated Phase 1 data from its DNA...
Cyclacel Announces Publication of Phase 2 Results for Sapacitabine in Elderly AML Patients in the Lancet Oncology
01 nov. 2012 07h00 HE
|
Cyclacel Pharmaceuticals, Inc.
Study Provides Support for SEAMLESS, an Ongoing, Phase 3, Registration-Directed Trial in Elderly Patients With Newly Diagnosed AML
Updated Survival Data From a Pilot Study and Lead-In Phase of...